Moderna President Stephen Hoge sells about $17 million of stock in planned option-exercise trades
Moderna President Stephen Hoge cashed in about $17 million of stock this week, selling roughly half of the shares he received from exercising long-held options.
According to a Form 4 filing Friday, Hoge exercised 152,905 stock options at $12.21 a share over Oct. 14 and Oct. 15 and sold 78,369 Moderna shares in the same two sessions. The filing says the trades were made under a Rule 10b5-1 trading plan he adopted on June 15, 2026.
On Oct. 14, he sold 38,774 shares at a weighted-average price of $213.47 and another 450 shares at $214.15. On Oct. 15, he sold 39,145 shares at a weighted-average $220.72. Taken together, the sales total about $17.0 million at the reported prices.
Because he kept about half of the exercised shares, Hoge's direct stake actually grew. He held 1,636,565 Moderna shares directly after the last reported trade, up from about 1.56 million before the first exercise, according to the filing.
The Form 4 also lists 151,933 shares held by a trust for the benefit of his spouse and children, and 4,116 shares held through Valhalla, LLC. Hoge disclaims beneficial ownership of the trust shares except to the extent of any pecuniary interest.
After the exercises, Hoge still holds 152,905 fully vested options at the same $12.21 strike, which expire on Feb. 23, 2027, the filing shows.
By the numbers
- Options exercised: 152,905 at $12.21
- Shares sold: 78,369 on Oct. 14–15, 2026
- Weighted-average sale prices: $213.47, $214.15 and $220.72
- Approximate proceeds: $17.0 million
- Direct holdings after the trades: 1,636,565 shares
- Remaining options: 152,905, expiring Feb. 23, 2027
Sources
- Moderna, Inc., Form 4 for Stephen Hoge (President), filed Oct. 16, 2026, accession 0001682852-26-000187
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.
Continue your research with IDD Pro
Get full access to IDD's market intelligence.